🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

11 recruiting trials

for Fibrosing Interstitial Lung Disease

Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases NCT06537934n/a1 site📍 Milan IRCCS San Raffaele A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients NCT05139719Phase 21 site📍 Beijing Sunshine Lake Pharma Co., Ltd. · Tests: HEC585 dose A, HEC585 dose B, Placebo Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact NCT07004595n/a1 site📍 Nantes Nantes University Hospital · Tests: Evaluation of patient frailty FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression NCT07540988Phase 3164 sites📍 Birmingham📍 Los Angeles📍 Newport Beach Boehringer Ingelheim · Tests: Nerandomilast, Placebo matching nerandomilast A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) NCT07366034Phase 347 sites📍 Los Angeles📍 Aurora📍 Baltimore Boehringer Ingelheim · Tests: Nerandomilast, Placebo Prospective Cohort of Patients With Fibrosing Interstitial Lung Disease Admitted for Acute Respiratory Failure NCT06855004n/a1 site📍 Bobigny Assistance Publique - Hôpitaux de Paris Domestic Environmental Exposure and Progression of ILD: An Exploratory Case-Control Study NCT07457502n/a2 sites📍 Paris📍 Paris Ville de Paris · Tests: Environmental audit of patient housing Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases NCT06440746Phase 2, Phase 333 sites📍 Barnaul📍 Chelyabinsk📍 Chelyabinsk R-Pharm International, LLC · Tests: Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL), SC in… Physical Activity and Fibrosing Interstitial Lung Disease NCT06182748NA1 site📍 Bobigny Assistance Publique - Hôpitaux de Paris · Tests: Training on eccentric ergocycle, Training on concentric ergocycle Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis NCT05988437n/a7 sites📍 Nantes📍 Ancenis📍 Angers Nantes University Hospital Study of ORJ-001 for the Treatment of IPF NCT07869147Phase 22 sites📍 Doral📍 DuBois Oorja Bio, Inc. · Tests: ORJ-001, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy